[ News ] [ Our People ]
[ Management Team ] [ Board of Directors ]
Mohr, Ph.D., ICD.D.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he
founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the
University of Ottawa until 1997 has over 30 years of experience in experimental
therapeutics of CNS disorders. He is credited with over 150 publications, book
chapters and abstracts and has edited the Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served on several
regulatory advisory panels for the approval of new products for the treatment of
neurodegenerative disease and is the former Chairman and Chief Executive Officer
of CroMedica Global Inc. (which merged with PRA International in 2002 to form
one of the world's leading contract research organizations) and is the current
or past Chairman of several biotechnology companies. His most recent executive
position was with PRA International as Chief Scientific Officer. He also served
until recently as Chair of the Board of Governors of the University of Victoria.
Over the course of his career, Dr. Mohr has overseen and/or participated in more
than a dozen clinical development programs resulting in a number of approved drugs.
Matthias Luz, M.D.
Dr. Luz, Chief Medical Officer at Atai Life Sciences, serves as a medical consultant for MedGenesis. He is a
board-certified anesthesiologist and previously served as Chief Medical Officer
for MedGenesis, with direct responsibility for all of the company’s development
activities. With more than 26 years in the biopharmaceutical industry on record,
Dr. Luz has extensive experience in preclinical and clinical drug development
including regulatory affairs. Prior to MedGenesis, Dr. Luz was the Vice
President and Head, Global Product Development Services for PRA International,
and held senior positions at Cardion, Abbott/Knoll, and Aventis/Hoechst Marion
Lara Longpre, M.Sc., MBA
Ms. Longpre serves as an operations consultant for MedGenesis. She is also
currently Chief Development Officer at Mirum Pharmaceuticals. She brings more
than 25 years of experience developing innovative and complex therapies. Lara
previously served as Chief Operating Officer for MedGenesis where she was
responsible for program management, alliance management, the intellectual
property portfolio, and business operations. Prior to MedGenesis, she served as
Chief Operating Officer for Jennerex, and held several senior positions with PRA
International/CroMedica including operations, regulatory affairs, and proposals
& contracts. She holds a BA in Biology from Cornell University, an M.M.S. from
Harvard Medical School and an MBA from Queen's University.